Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.

  title={Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.},
  author={David W. Goodman},
  journal={P & T : a peer-reviewed journal for formulary management},
  volume={35 5},
  • David W. Goodman
  • Published 2010 in
    P & T : a peer-reviewed journal for formulary…
the impact of ADHD on workplace productivity and costs to employers has focused on the need to increase the diagnosis and treatment of ADHD in adults.13 The study, conducted by Kessler et al. at a large manufacturing firm and published in 2009, found that ADHD was associated with a 4% to 5% reduction in on-the-job productivity, the equivalent of losing 10 to 12 work days in a 250-day work year. The cost to employers for lost work performance was estimated to be $4,336 per employee with ADHD… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
10 Citations
59 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 59 references

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a DRUG REVIEW: Lisdexamfetamine (Vyvanse) for ADHD

  • L Adler, R Weisler, D Goodman
  • J Clin Psychiatry
  • 2010

Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine. Poster presented at the annual meeting of the New Clinical Drug Evaluation Unit

  • M. Pennick
  • June 29–July
  • 2009

Efficacy and safety of lisdexamfetamine dimesylate in adults with attention - deficit / hyperactivity disorder in the adult workplace environment

  • M Brams
  • Behav Brain Func
  • 2009

Similar Papers

Loading similar papers…